Endometriosis, a prevalent gynecological disease affecting women's health, involves altered immune function. This study investigates the immune checkpoint protein, V-domain immunoglobulin suppressor of T cell activation (VISTA) as a therapeutic …
Deep infiltrating endometriosis (DIE) often affects the bowel and may necessitate colorectal resection. While protective ileostomy can reduce complications, it carries relevant morbidity. This study evaluates endoscopic complication management and …
Bisphenols and per- and polyfluoroalkyl substances (PFAS) are ubiquitous environmental endocrine-disrupting chemicals with widespread human exposure and growing concern regarding their reproductive toxicity. This review integrates current experimental and epidemiologic …
To develop a Workplace Health Initiatives Checklist for Women (WHIC‑W), we assessed content validity (expert) and provided initial evidence for construct validity by examining hypothesized cross-sectional associations with burnout, productivity, …
Endometriosis is a substantial public health challenge, affecting nearly 10% of women of reproductive age. Given the therapeutic benefits of elagolix over conventional therapies, along with the growing body of …
Drug-drug interactions (DDIs) represent a major preventable cause of medication-related harm globally. Their prevalence varies across health systems, but common drivers include polypharmacy, aging populations, and specialty-specific prescribing patterns. Large-scale …
Background: Women with endometriosis frequently experience mobility limitations that affect daily functioning. A specific tool to assess these restrictions would help clinicians to better understand patients' functional challenges, facilitating more …
The current mixed-methods study aimed to investigate how individuals experiencing endometriosis coped and adapted to their condition, and the extent to which coping predicted health-related quality of life (HRQoL) over …
Endometriosis is a chronic gynecological condition affecting approximately 10% of women of reproductive age worldwide and is associated with chronic pelvic pain, infertility, and reduced quality of life. In Brazil's …
Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …